PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
January 1, 2011Circulation Journal200 citationsOpen Access

Present Status of Anticoagulation Treatment in Japanese Patients With Atrial Fibrillation - A Report From the J-RHYTHM Registry -

HAHirotsugu AtarashiHIHiroshi InoueKOKen Okumura

Key Result

In a registry of Japanese outpatients with atrial fibrillation, 87.3% were taking warfarin, of whom 66.0% had an INR between 1.6 and 2.6.

Study Design

Type

Observational (n=7,937)

Multicenter

Yes

Structured PICO

P
Population
7,937 patients with atrial fibrillation (5,468 men, 2,469 women) registered from 158 institutions in Japan.
I
Intervention
Anticoagulation treatment (warfarin)
O
Outcome
Status of anticoagulation treatment (warfarin use rate and INR range)

Warfarin is extensively used in Japanese AF patients, including those with low stroke risk (CHADS2 0-1), with many patients maintained at lower INR ranges.

Limitations

  • Registry was established only in selected institutions and does not include general practitioner clinics.
  • Clinical backgrounds of the patients were investigated only at registration (cross-sectional data).
  • Did not investigate the type of drug used for rate or rhythm control.
  • Did not assess the risk of bleeding complications with anticoagulation treatment.

Abstract

BACKGROUND: Underuse and an inadequate range for the international normalized ratio (INR) for warfarin use are still problems in the management of the patients with atrial fibrillation (AF) in Japan. METHODS AND RESULTS: From January to July 2009, a total of 7,937 AF patients 5,468 men (68.6 ± 10.0 years) and 2,469 women (72.2 ± 9.0 years) were registered from 158 institutions for the J-RHYTHM Registry. Overall, 34.2% of the patients were over the age of 75. The associated cardiovascular diagnoses were hypertension in 59.1%, coronary artery disease in 10.1%, cardiomyopathy in 8.3%, valvular heart disease in 13.7% and artificial cardiac valves in 3.1% of the patients. The type of AF was paroxysmal in 37.1%, persistent in 14.4%, and permanent in 48.5%. Overall, 87.3% of patients were taking warfarin (2.9 ± 1.2mg/day), of whom 66.0% had an INR between 1.6 and 2.6, and 35.4% were in the INR range from 2.0 to 3.0 at the time of registration. Aspirin was prescribed in 22.3% of cases. The CHADS2 score was 0 in 15.7% of patients, 1 in 34.0%, and ≥ 2 in 50.3%. CONCLUSIONS: At present, warfarin is used extensively in patients with AF whose stroke risk is relatively low (ie, in Japan) and half of them had CHADS2 scores of 0 to 1 (UMIN Clinical Trials Registry UMIN000001569).

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Atarashi et al. (2011) conducted an observational in Atrial Fibrillation (n=7,937). Warfarin vs. No warfarin was evaluated on Warfarin use. In a registry of Japanese outpatients with atrial fibrillation, 87.3% were taking warfarin, of whom 66.0% had an INR between 1.6 and 2.6.

synapsesocial.com/papers/6a179117d990e918e6b43b9fhttps://doi.org/10.1253/circj.cj-10-1119
Ask AI
Helpful
Bookmark
Share
View Full Paper